Skip to main content

Table 1 Summary of gene annotation enrichment analyses of BRAT- and PUM-associated mRNAs

From: Brain tumor is a sequence-specific RNA-binding protein that directs maternal mRNA clearance during the Drosophila maternal-to-zygotic transition

 

All PUM-associated mRNAs

mRNAs associated only with PUM

All BRAT-associated mRNAs

mRNAs associated only with BRAT

PUM and BRAT co-target mRNAs

Biological and developmental

Embryonic pattern specification

+++

++

.

.

.

Axis specification

++

.

+

.

+

Embryonic morphogenesis/gastrulation

++++

+++

.

.

.

Formation of organ boundary

++++

++++

.

.

.

Imaginal disc development/pattern formation

++++

+++

.

.

.

Oogenesis/ovarian follicle cell development

++

+

.

.

.

Neuroblast fate determination

+

.

.

.

+

Tube development/digestive system development/respiratory system development

++

+

.

.

.

Salivary gland development

+

+

.

.

.

Sensory organ development

+++

++

.

.

.

Cellular

Cell motility/cell migration

+++++

+++

.

.

+

Neuron projection morphogenesis

+++

++

.

.

.

Cell division/asymmetric cell division

+

+

.

.

.

Cell adhesion

+

+

.

.

.

Regulation of growth/cell size

++

++

.

.

.

Regulation of apoptosis

+

.

.

.

.

Molecular

Signal transduction

+++++

++++

+

.

+++

Regulation of transcription

++++

+++

.

.

+

Protein kinase activity

++

.

+

.

.

Phosphatase activity

.

.

+

.

.

Glycosyltransferase

++

+

.

.

.

Integral membrane proteins

++++

+

+++++

+++

+++

Glycoproteins

+++

++

.

.

.

Ion transport/homeostasis

.

.

+++

++

+

Phospholipid/phosphoinositide metabolism

.

.

+++

+++

.

  1. + FDR = 1% to 10%; ++ FDR = 0.1% to 1%; +++ FDR = 0.001% to 0.1%; ++++ FDR = 10−5% to 0.001%; +++++ FDR <10−5%; ‘.’ = not significant (FDR >10% and Benjamini P value >0.1). FDR values represent the most significantly enriched annotation term related to the function listed. Analyses were performed using the DAVID functional annotation tool [42,43]. For details see Additional file 8.